Forte Biosciences (FBRX) Current Assets (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Current Assets data on file, last reported at $65.1 million in Q1 2026.

• On a quarterly basis, Current Assets rose 38.07% year-over-year to $65.1 million in Q1 2026; TTM through Mar 2026 was $65.1 million, a 38.07% increase from a year earlier, with the FY2025 full-year figure at $80.6 million, up 31.37% from the prior year.
• Current Assets for Q1 2026 stood at $65.1 million, down from $80.6 million in the prior quarter.
• Over the last five years, Current Assets for FBRX reached as high as $107.6 million in Q2 2025 and fell as low as $17.7 million in Q3 2024.
• Historically, Current Assets has averaged $50.0 million across 5 years, with a median of $41.5 million in 2022.
• Across the five-year window, Current Assets tumbled 62.49% in 2024 and surged 440.03% in 2025, its largest moves.
• Year by year, Current Assets stood at $41.5 million in 2022, then dropped by 7.67% to $38.3 million in 2023, then soared by 60.06% to $61.3 million in 2024, then surged by 31.37% to $80.6 million in 2025, then slipped by 19.21% to $65.1 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $65.1 million in Q1 2026, $80.6 million in Q4 2025, and $95.4 million in Q3 2025.